Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Surgery Partners (SGRY) over the last 12 years, with Q3 2025 value amounting to $12.2 million.

  • Surgery Partners' Gains from Investment Securities rose 33571.43% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.0 million, marking a year-over-year increase of 6355.14%. This contributed to the annual value of $24.8 million for FY2024, which is 5069.58% down from last year.
  • Latest data reveals that Surgery Partners reported Gains from Investment Securities of $12.2 million as of Q3 2025, which was up 33571.43% from $8.6 million recorded in Q2 2025.
  • In the past 5 years, Surgery Partners' Gains from Investment Securities registered a high of $56.5 million during Q2 2022, and its lowest value of -$700000.0 during Q3 2021.
  • Moreover, its 5-year median value for Gains from Investment Securities was $7.8 million (2024), whereas its average is $11.3 million.
  • Per our database at Business Quant, Surgery Partners' Gains from Investment Securities tumbled by 15000.0% in 2021 and then skyrocketed by 2815000.0% in 2022.
  • Quarter analysis of 5 years shows Surgery Partners' Gains from Investment Securities stood at $1.8 million in 2021, then soared by 1527.78% to $29.3 million in 2022, then crashed by 99.66% to $100000.0 in 2023, then surged by 3400.0% to $3.5 million in 2024, then soared by 248.57% to $12.2 million in 2025.
  • Its last three reported values are $12.2 million in Q3 2025, $8.6 million for Q2 2025, and $10.7 million during Q1 2025.